Literature DB >> 30135508

HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions.

Marjolein van Zummeren1, Wieke W Kremer1, Annemiek Leeman2, Maaike C G Bleeker1, David Jenkins2, Miekel van de Sandt2, John Doorbar3, Daniëlle A M Heideman1, Renske D M Steenbergen1, Peter J F Snijders1, Gemma G Kenter4, Wim G V Quint2, Johannes Berkhof5, Chris J L M Meijer6.   

Abstract

In this study, we evaluate the expression of human papillomavirus E4 protein (marker for the onset of a productive infection) and hypermethylation of host-cell CADM1, MAL, and miR124-2 genes (marker for an advanced, transforming infection) in cervical intraepithelial neoplasia (CIN) and cancer. A total of 115 cervical lesions were categorized by 3 pathologists into no dysplasia, CIN1, CIN2, CIN3, or cancer by classical histomorphological grading criteria, and by an immunoscore (cumulative value: 0-6) grading system based on Ki-67 (score: 0-3) and p16ink4a (score: 0-3) expression. Lesions were immunostained for E4 protein and analyzed for hypermethylation of CADM1, MAL, or miR124-2 genes. Expression of E4 and hypermethylation levels were related to CIN grade based on both classical and immunoscore grading. Hypermethylation increased with severity of the lesion as defined by both classical histomorphological grading and immunoscore criteria, and was always present in carcinomas (22/22). Extensive E4 expression decreased with increasing CIN grade and immunoscore, being most frequent in classically graded CIN1 or in lesions with cumulative immunoscore 1-3 and absent in carcinomas. High-grade lesions (CIN2/3 or immunoscore: 4-6) showed less E4 expression, which was inversely related to an increasing hypermethylation. Extensive E4 expression, as observed in a small proportion of high-grade lesions (6/49 and 8/43, respectively), was mostly associated with a negative methylation marker status (5/6 and 7/8, respectively). Our results illustrate the gradual transition of productive CIN (reflected by extensive E4 expression), to advanced transforming CIN (reflected by extensive hypermethylation) and cancer. Expression patterns of E4 and hypermethylation status of host-cell genes, may be used to identify cervical lesions at risk for cervical cancer, providing a better guidance for clinicians on treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30135508     DOI: 10.1038/s41379-018-0101-z

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  16 in total

1.  Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers.

Authors:  Wanxue Xu; Mengyao Xu; Longlong Wang; Wei Zhou; Rong Xiang; Yi Shi; Yunshan Zhang; Yongjun Piao
Journal:  Signal Transduct Target Ther       Date:  2019-12-13

Review 2.  Epigenetic and Transcriptomic Regulation Landscape in HPV+ Cancers: Biological and Clinical Implications.

Authors:  Rosario Castro-Oropeza; Patricia Piña-Sánchez
Journal:  Front Genet       Date:  2022-06-14       Impact factor: 4.772

3.  Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 (CIN2): protocol for a historical cohort study.

Authors:  Rikke Kamp Damgaard; David Jenkins; Maurits Nc de Koning; Wim Gv Quint; Mark H Stoler; John Doorbar; Johnny Kahlert; Patti E Gravitt; Torben Steiniche; Lone Kjeld Petersen; Anne Hammer
Journal:  BMJ Open       Date:  2022-07-06       Impact factor: 3.006

Review 4.  The MAL Protein, an Integral Component of Specialized Membranes, in Normal Cells and Cancer.

Authors:  Armando Rubio-Ramos; Leticia Labat-de-Hoz; Isabel Correas; Miguel A Alonso
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

5.  Classification of high-grade cervical intraepithelial neoplasia by p16ink4a , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management.

Authors:  Frederique J Vink; Stèfanie Dick; Daniëlle A M Heideman; Lise M A De Strooper; Renske D M Steenbergen; Birgit I Lissenberg-Witte; Arno Floore; Jesper H Bonde; Anja Oštrbenk Valenčak; Mario Poljak; Karl U Petry; Peter Hillemanns; Nienke E van Trommel; Johannes Berkhof; Maaike C G Bleeker; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2021-05-11       Impact factor: 7.396

6.  Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance.

Authors:  Xinlin Jiao; Siying Zhang; Jun Jiao; Teng Zhang; Wenjie Qu; Guy Mutangala Muloye; Beihua Kong; Qing Zhang; Baoxia Cui
Journal:  Clin Epigenetics       Date:  2019-08-19       Impact factor: 6.551

7.  Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers.

Authors:  Wanxue Xu; Mengyao Xu; Longlong Wang; Wei Zhou; Rong Xiang; Yi Shi; Yunshan Zhang; Yongjun Piao
Journal:  Signal Transduct Target Ther       Date:  2019-12-13

8.  Three-tiered score for Ki-67 and p16ink4a improves accuracy and reproducibility of grading CIN lesions.

Authors:  Annemiek Leeman; Wieke W Kremer; Marjolein van Zummeren; Maaike C G Bleeker; David Jenkins; Miekel van de Sandt; Daniëlle A M Heideman; Renske Steenbergen; Peter J F Snijders; Wim G V Quint; Johannes Berkhof; Chris J L M Meijer
Journal:  J Clin Pathol       Date:  2018-07-16       Impact factor: 3.411

9.  The use of molecular markers for cervical screening of women living with HIV in South Africa.

Authors:  Wieke W Kremer; Marjolein van Zummeren; Erika Breytenbach; Karin L Richter; Renske D M Steenbergen; Chris J L M Meijer; Greta Dreyer
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

10.  An epigenomic landscape of cervical intraepithelial neoplasia and cervical cancer using single-base resolution methylome and hydroxymethylome.

Authors:  Yingxin Han; Liyan Ji; Yanfang Guan; Mengya Ma; Pansong Li; Yinge Xue; Yinxin Zhang; Wanqiu Huang; Yuhua Gong; Li Jiang; Xipeng Wang; Hong Xie; Boping Zhou; Jiayin Wang; Junwen Wang; Jinghua Han; Yuliang Deng; Xin Yi; Fei Gao; Jian Huang
Journal:  Clin Transl Med       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.